V J Marder
Affiliation: University of California
- Short-term effects of air pollution: a panel study of blood markers in patients with chronic pulmonary diseaseKatharina Hildebrandt
Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Institute of Epidemiology, Munich, Germany
Part Fibre Toxicol 6:25. 2009..abstract:..
- Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic strokeVictor J Marder
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles Orthopaedic Hospital, 2400 S Flower St, Los Angeles, California 90007, USA
Stroke 37:2086-93. 2006..Information regarding the histological structure of thromboemboli that cause acute stroke provides insight into pathogenesis and clinical management...
- Maximized hemostasisVictor J Marder
Los Angeles Orthopaedic Hospital, University of California, Los Angeles School of Medicine, 90007, USA
Thromb Haemost 87:555-6. 2002
- The interaction of dietary supplements with antithrombotic agents: scope of the problemVictor J Marder
Division of Hematology Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90007, USA
Thromb Res 117:7-13; discussion 39-42. 2005
- Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbitV J Marder
Vascular Medicine Program, Los Angeles Orthopaedic Hospital University of California, 90007, USA
Thromb Haemost 86:739-45. 2001..These results suggest that plasmin is an effective, unique thrombolytic agent, distinguished from the plasminogen activators in current usage by its striking safety profile...
- Foundation and sites of action of antithrombotic agentsVictor J Marder
Vascular Medicine Program, Los Angeles Orthopedic Hospital, and Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, CA, USA
Best Pract Res Clin Haematol 17:3-22. 2004..In this review, we discuss mechanisms of hemostasis in relation to antithrombotic agents and results of clinical trials using these drugs...
- Cocaine and Buerger disease: is there a pathogenetic association?V J Marder
Vascular Medicine Program, Orthopaedic Hospital, 2400 S Flower St, Los Angeles, CA 90007, USA
Arch Intern Med 160:2057-60. 2000....
- Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research InvestigatorsV J Marder
Orthopaedic Hospital UCLA School of Medicine, Los Angeles, CA, USA
Thromb Haemost 82:1412-6. 1999..003 and p = 0.001, respectively). This is the first demonstration that a latex agglutination assay for D-dimer can be used to assess the prognostic risk of recurrent coronary thrombotic disease after myocardial infarction..
- Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleedingS Sadeghi
Vascular Medicine Program, Los Angeles Orthopedic Hospital, and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90007, USA
J Thromb Haemost 1:2621-5. 2003..These data indicate that in the rabbit, concomitant use of aspirin plus heparin does not affect the safety of a therapeutic dose of plasmin...
- Magnesium sulfate neither potentiates nor inhibits tissue plasminogen activator-induced thrombolysisD Stewart
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
J Thromb Haemost 4:1575-9. 2006..Increasing circulating magnesium concentrations to 2-fold over normal baseline may afford a neuroprotective effect in patients with acute cerebral ischemia...
- Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potentialV J Marder
Hematology Medical Oncology Division, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Thromb Haemost 8:433-44. 2010..Whether direct fibrinolytics will provide clinical superiority in major thrombotic disorders over currently utilized indirect fibrinolytics such as tissue plasminogen activator remains to be determined...
- Current issues concerning thrombolytic therapy for acute myocardial infarctionC H Hennekens
Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
J Am Coll Cardiol 25:18S-22S. 1995..Whether or not accelerated t-PA has a small advantage for mortality is less conclusive.(ABSTRACT TRUNCATED AT 250 WORDS)..
- Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparinS Chan
Vascular Medicine Program, Los Angeles Orthopaedic Hospital, Los Angeles, CA 90007, USA
J Thromb Haemost 1:760-5. 2003..However, the bolus injection of LMWH produced a very high blood anti-FXa level, which may have precluded rFVIIa effectiveness...
- Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I resultsV J Marder
Division of Hematology Medical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
J Thromb Haemost 10:985-91. 2012..Plasmin is a direct-acting thrombolytic with a striking safety advantage over PA in preclinical models...
- Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO InvestigatorsW Zareba
Department of Medicine, University of Rochester Medical Center, NY 14642, USA
Thromb Haemost 86:791-9. 2001....
- Historical perspective and future direction of thrombolysis research: the re-discovery of plasminV J Marder
Division of Hematology and Medical Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
J Thromb Haemost 9:364-73. 2011..After more than 50 years, the field has come full circle, and plasmin as the thrombolytic agent and catheter use for local delivery of agent may represent a step forward in thrombolytic therapy...
- Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragmentS E Martin
Hematology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Thromb Res 31:437-49. 1983..This chain may possess critical features that mimic the optimal structure of vW protein that forms intercellular bridges and promotes agonist stimulation by WGA via membrane receptors...
- Proteasome-independent activation of nuclear factor kappaB in cytoplasmic extracts from human endothelial cells by Rickettsia rickettsiiS K Sahni
Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642, USA
Infect Immun 66:1827-33. 1998..rickettsii may interact with and activate host cell transcriptional machinery independently of the involvement of the proteasome or known signal transduction pathways...
- Cloning of guinea pig tissue factor cDNA: comparison of primary structure among six mammalian speciesR J Shi
Department of Medicine, University of Rochester, School of Medicine and Dentistry, NY, USA
Thromb Haemost 83:455-61. 2000..We hypothesize that divergence at these regions contributes to the specificity and non-reciprocity of TF procoagulant activity between species...
- Acquired thrombophilic syndromesD Matei
Vascular Medicine Program, Los Angeles Orthopaedic Hospital University of California at Los Angeles, Los Angeles, CA 90007, USA
Blood Rev 15:31-48. 2001..All of these factors can directly influence thrombus formation and/or the physiologic response to the thrombus.(1)..
- Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhageDaphne Stewart
Vascular Medicine Program, Los Angeles Orthopaedic Hospital, The David Geffen School of Medicine at UCLA, University of California Los Angeles, CA 90007, USA
Blood 101:3002-7. 2003..Plasmin has a 6-fold margin of safety, in contrast with TPA, which causes hemorrhage at thrombolytic dosages...
- Towards safer thrombolytic therapyVictor J Marder
Department of Vascular Medicine, Los Angeles Orthopaedic Hospital, 2400 S Flower Street, Los Angeles, CA 90007, USA
Semin Hematol 39:206-16. 2002..Animal studies are fully consistent with this approach, which offers potential for achieving a truly regional thrombolytic treatment...
- Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysisReza Jahan
Stroke 39:1613-5. 2008..We describe a technique for MCA thrombo-occlusion in the rabbit with real-time angiographic documentation of occlusion and thrombolytic recanalization...
- Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patientsTareq S Harb
Cardiology Unit, Department of Medicine, University of Rochester Medical Center, New York 14642, USA
Am J Cardiol 91:1120-3. 2003
- Conference summary and recommendations for researchAhmed A K Hasan
Thrombosis and Hemostasis Program, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda, MD 20892, USA
Thromb Res 117:229-30. 2005
- Opinions and research prioritiesHenry I Bussey
College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
Thromb Res 117:155-69; discussion 170-4. 2005
- Use of thrombolytic therapy for acute myocardial infarction: effects of gender and age on treatment ratesKaren L Kaplan
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
J Thromb Thrombolysis 13:21-6. 2002..This study was undertaken to determine the relative rates of treatment of women vs. men and the elderly vs. younger subjects and to examine factors that might explain differences in treatment frequency...
- Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?Valery V Novokhatny
Biological Products Division, Bayer HealthCare, PO Box 13887, 85 TW Alexander Drive, Research Triangle Park, NC 27709, USA
Trends Pharmacol Sci 25:72-5. 2004..These results predict that plasmin will prove to be both superior to, and safer than, plasminogen activators in the dissolution of long, retracted blood clots in humans...
- History of hypertension and enhanced thrombogenic activity in postinfarction patientsYazid Y Fadl
Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Box 653, Rochester, NY 14642, USA
Hypertension 41:943-9. 2003..02, P=0.005) and nonhypertensive (hazard ratio=2.42, P=0.02) patients. Thus, patients after infarction with a history of hypertension have enhanced thrombogenic activity, which predisposes them to recurrent cardiac events...
- Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patientsJames P Corsetti
Department of Pathology and Laboratory Medicine, School of Medicine and Dentistry, University of Rochester, P O Box 626, 601 Elmwood Avenue, Rochester, NY, USA
Atherosclerosis 171:351-8. 2003....
- SAFER THROMBOLYTIC THERAPY USING PLASMINVictor Marder; Fiscal Year: 2007..We hypothesize and anticipate that plasmin will provide clinically effective thrombolysis without an increased risk of bleeding . ..